Gilead
 
Corporate Overview

Advancing Therapeutics, Improving Lives

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world. Gilead's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.

Our portfolio of 14 marketed products includes a number of category firsts, including the only complete treatment regimens for HIV infection available in a once-daily single pill – Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), approved in 2006, and Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate), approved in 2011.

More Than 20 Years of Growth

Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,500 employees in offices across four continents.

In 2010, Gilead’s annual revenues reached nearly $8 billion, and in 2009, BusinessWeek ranked Gilead #1 in its annual listing of the 50 Best-Performing Companies.

Our Marketed Products

Following is a summary of Gilead’s product portfolio. See our Products section for full prescribing information, including BOXED WARNINGS and Important Safety Information.

HIV/AIDS

  • Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is a once-daily single-tablet regimen for the treatment of HIV infection in adults. Atripla combines three HIV medicines in a single pill: Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb Company. (U.S. approval, 2006; EU approval, 2007.)
  • Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a once-daily complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naíve adults. Complera combines three medicines in a single pill: Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine) and Edurant® (rilpivirine), manufactured by Tibotec Pharmaceuticals Ltd. (U.S. and EU approval, 2011; marketed as Eviplera® in the EU.)
  • Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection. An oral solution is available for use in pediatric patients. (U.S. and EU approval, 2003.)
  • Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread and Emtriva. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. (U.S. approval, 2004; EU approval, 2005.)
  • Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in patients 2 years of age and older in combination with other antiretroviral agents. (First U.S. approval, 2001; EU approval, 2002.) Viread is also approved as a treatment for chronic hepatitis B in adults. (U.S. and EU approval, 2008.)

Liver Disease

  • Hepsera® (adefovir dipivoxil) is a once-daily oral NtRTI for the treatment of chronic hepatitis B in patients 12 years of age and older. (U.S. approval, 2002; EU approval, 2003.)
  • Viread® (tenofovir disoproxil fumarate) is a once-daily oral NtRTI for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated and decompensated liver disease. (U.S. and EU approval, 2008.) As noted above, Viread is also approved for the treatment of HIV infection in patients 2 years of age and older in combination with other antiretroviral agents.

Cardiovascular

  • Letairis® (ambrisentan) is a once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms. (U.S. approval, 2007; EU approval, 2008, as Volibris®. GlaxoSmithKline PLC holds rights to commercialize the product outside of the United States.)
  • Lexiscan® (regadenoson) injection is the first A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging studies. The product has been designed to target the A2A adenosine receptor, which is the adenosine receptor subtype responsible for coronary vasodilation. (U.S. approval, 2008; EU approval, 2010, as Rapiscan®. Astellas Pharma US, Inc. commercializes the product in the United States. Rapidscan Pharma Solutions, Inc. commercializes the product in Europe.)
  • Ranexa® (ranolazine) is an extended-release tablet for the treatment of chronic angina. Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers. (U.S. approval, 2006; U.S. indication updated to include first-line treatment for chronic angina, 2008; EU approval, 2008.)

Respiratory

  • Cayston® (aztreonam for inhalation solution) is an inhaled antibiotic indicated to improve respiratory symptoms in cystic fibrosis (CF) patients 7 years of age and older with Pseudomonas aeruginosa infection. Cayston is administered with the Altera® Nebulizer System, a portable, drug-specific delivery device using the eFlow® Technology Platform, developed by PARI Pharma GmbH. (EU conditional approval, 2009; U.S. approval, 2010.)
  • Tamiflu® (oseltamivir phosphate) is the first neuraminidase inhibitor tablet for the treatment and prevention of influenza A and B. Developed by Gilead, Tamiflu is commercialized globally by F. Hoffmann-La Roche Ltd. (U.S. approval for influenza treatment, 1999; U.S. indication expanded to include influenza prevention, 2000; EU approval, 2002.)

Other

  • AmBisome® (amphotericin B liposome for injection) is a treatment for life-threatening, systemic fungal infections in adults. (EU approval, 1990; U.S. approval, 1997. Astellas Pharma US, Inc. commercializes the product in the U.S. and Canada.)
  • Macugen® (pegaptanib sodium injection) is an injection for the treatment of neovascular age-related macular degeneration (also known as "wet" AMD), an eye disease that destroys central vision in elderly patients. (U.S. approval, 2004; EU approval, 2006. Macugen is marketed in the U.S. by Eyetech Inc., and by Pfizer Inc. outside the U.S.)
  • Vistide® (cidofovir injection) is an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS. (U.S. approval, 1996; EU approval, 1997.)

Science and Research

Gilead's research and development program identifies and evaluates compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

HIV/AIDS

  • The Quad is a once-daily, single-tablet regimen being evaluated for the treatment of HIV. It combines four medicines into a single pill: elvitegravir (an investigational integrase inhibitor), cobicistat (an investigational pharmacoenhancing or "boosting" agent) and the two component drugs of Truvada. An application for marketing approval of the Quad is currently under review in the United States and Europe.
  • Elvitegravir is one of the first candidates in a new class of HIV drugs known as integrase inhibitors. Unlike other classes of antiretroviral agents, integrase inhibitors interfere with HIV replication by blocking the ability of the virus to integrate into the genetic material of human cells. (Phase 3)
  • Cobicistat is an investigational compound being developed as a pharmacoenhancing or "boosting" agent to increase blood levels and allow once-daily dosing for certain HIV medicines, including elvitegravir. It is also being studied as a boosting agent for other antiretrovirals, in particular, protease inhibitors. (Phase 3)
  • GS-7340 is a novel prodrug of tenofovir, the active agent in Viread, that has the potential to provide greater antiviral efficacy at a dose ten times lower than Viread. It is being studied as a treatment for HIV infection. (Phase 2)

Liver Disease

  • GS-7977 is an oral nucleotide NS5B inhibitor being studied for the treatment of hepatitis C (HCV) infection. (Phase 3)
  • GS-6624 is a human monoclonal antibody (mAb) that is being studied as a treatment for liver fibrosis. (Phase 2)
  • Tegobuvir/GS-9190 is an oral non-nucleoside NS5B inhibitor being studied for the treatment of HCV infection. (Phase 2)
  • GS-9256 is an oral NS3 protease inhibitor being studied for the treatment of HCV infection. (Phase 2)
  • GS-9451 is an oral NS3 protease inhibitor being studied for the treatment of HCV infection. (Phase 2)
  • GS-5885 is an oral NS5A inhibitor being studied for the treatment of HCV infection. (Phase 2)
  • GS-9620 is an oral TLR-7 agonist being studied for the treatment of HBV and HCV infection. (Phase 1)
  • GS-9669 is an oral non-nucleoside NS5B site 2 inhibitor being studied for the treatment of HCV infection. (Phase 1)

Cardiovascular/Metabolic

  • Ranolazine is an oral late sodium current inhibitor agent that is already approved in the United States as Ranexa for the treatment of chronic angina, and is also being studied as a treatment for incomplete revascularization post-percutaneous coronary intervention (PCI) (Phase 3) and Type 2 diabetes. (Phase 3)

Respiratory

  • Aztreonam for inhalation solution is an antibiotic that is already approved in the United States as Cayston for the treatment of CF patients with Pseudomonas aeruginosa infection, and is also being studied as a treatment for patients with bronchiectasis. (Phase 3)
  • GS-6624 is also being studied as a treatment for idiopathic pulmonary fibrosis. (Phase 1)

Inflammation/Oncology

  • GS-1101 is a PI3K delta-specific inhibitor that is being studied as a treatment for chronic lymphocytic leukemia (Phase 3) and refractory indolent non-Hodgkin’s lymphoma. (Phase 2)
  • GS-6624 is also being studied as a treatment for colorectal cancer (Phase 2), myelofibrosis (Phase 2) and pancreatic cancer. (Phase 2)
  • GS-9973 is an oral spleen tyrosine kinase (Syk) inhibitor being studied as a treatment for rheumatoid arthritis. (Phase 1)

Aztreonam for inhalation solution for bronchiectasis, cobicistat, elvitegravir, GS-1101, GS-5885, GS-6624, GS-7340, GS-9256, GS-9451, GS-9620, GS-9669, GS-9973, GS-7977, the Quad, ranolazine for incomplete revascularization post-PCI and Type 2 diabetes, and tegobuvir/GS-9190 are investigational treatments and have not yet been determined safe or efficacious in humans.

Growing Worldwide Footprint

Gilead has approximately 4,500 employees around the world. Corporate headquarters are located in Foster City, California. We also have additional operations in:

North American Locations

  • Foster City, CA (Headquarters)
  • Oceanside, CA
  • Palo Alto, CA
  • San Dimas, CA
  • Branford, CT
  • Princeton, NJ
  • Seattle, WA
  • Alberta, Canada
  • Ontario, Canada

International Locations

  • Stockley Park, UK (International Headquarters)
  • Cambridge, UK
  • Australia/New Zealand
  • Austria
  • Benelux (with offices in Belgium and the Netherlands)
  • China
  • France
  • Germany
  • Greece
  • Hong Kong (Asia Headquarters)
  • Ireland
  • Italy
  • Korea
  • Nordic and Baltic Regions (with an office in Sweden)
  • Poland
  • Portugal
  • Spain
  • Switzerland
  • Turkey

Corporate Responsibility

As Gilead grows as a company, so do our responsibilities as a corporate citizen. We strive to play our part in expanding global access to our medications and to give back to the communities in which we operate. To this end, we are undertaking the following initiatives:

  • Gilead Access Program
    Gilead recognizes the urgent need for access to HIV medications worldwide, particularly in developing countries where the AIDS epidemic is devastating communities. We believe that the medicines we develop should be accessible to all patients who need them worldwide, regardless of income or location. Since early 2003, we have operated an access program to provide our HIV medications at substantially reduced prices in 132 low- and lower middle-income countries. As a result of this program, approximately 2.1 million patients in the developing world are now receiving Gilead’s therapies for the treatment of HIV.
  • Partnerships with Generic Manufacturers and Medicines Patent Pool
    Gilead has signed non-exclusive licenses with multiple generic manufacturers in India and South Africa. Under these agreements, our Indian partners are producing high-quality, low-cost generic versions of Viread and Viread-containing regimens in 112 resource-limited countries. Gilead is also the first pharmaceutical company to sign an agreement with the Medicines Patent Pool Foundation, which is working to increase global access to high-quality, low-cost antiretroviral therapy through the sharing of patents. The Patent Pool has been granted similar licensing terms for Gilead’s HIV medicines as our Indian partners, including a license for Viread and Truvada and future rights to medicines completing late-stage clinical development.
  • Fighting Visceral Leishmaniasis in the Developing World
    We work closely with the World Health Organization and numerous non-governmental organizations to provide AmBisome at a preferential price for the treatment of visceral leishmaniasis in resource-limited settings. Visceral leishmaniasis is the second-largest parasitic killer in the world, responsible for more than 60,000 deaths per year. In December of 2011, Gilead signed a partnership agreement with WHO to donate 445,000 vials of AmBisome over five years. This donation, which is equivalent to $8 million in product if sold at the no-profit access price, will be used to treat more than 50,000 patients in resource-limited countries.
  • Patient Access in the United States
    Gilead supports a number of programs for eligible patients in the United States who do not have insurance, are underinsured or who otherwise need financial assistance. These programs include U.S. Advancing Access®, Atripla® Patient Access Program, Gilead™Solutions, the Cayston® Access Program and Ranexa Connect™.
  • Screening, Diagnosis and Linkages to Care
    Gilead is actively involved in multiple local community partnerships at the grassroots level that focus on expanding screening programs for HIV/AIDS and that encourage patients to take an active role in their treatment and link them to prompt, appropriate medical care. Gilead is also helping to strengthen community-level public health efforts to expand screening programs for hepatitis B. In the United States, this work focuses on Asian American communities, where hepatitis B hits the hardest and where significant stigma and misconceptions about the disease persist.
  • The Gilead Foundation
    Established in 2005, the Gilead Foundation supports domestic and international programs, many focused on building local capacity and improving health infrastructure in the developing world.
  • Ongoing Research Collaborations
    We are also working with academic, government and private sector partners to better understand the profile of our products in important areas such as pediatric HIV care, prevention of mother-to-child HIV transmission, pre-exposure prophylaxis, and co-infection with HIV and tuberculosis or hepatitis B. Gilead actively supports clinical studies in more than 55 countries by providing product donations.

Please visit our Corporate Giving and Grants section for more information on Gilead's work in our communities.

Leadership

Following is a list of Gilead's Executive Committee. See the Leadership section for biographies of these individuals as well as Gilead's Board of Directors.

More Information

For more information about Gilead, its products or community involvement, please contact Gilead Public Affairs at +1 (650) 574-3000 or submit a media inquiry.